CervoMed, Inc. (CRVO)
2.44
+0.01
(+0.41%)
USD |
NASDAQ |
Sep 21, 16:00
2.44
0.00 (0.00%)
After-Hours: 20:00
CervoMed Enterprise Value : 7.930M for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 7.930M |
| September 17, 2026 | 9.554M |
| September 16, 2026 | 8.066M |
| September 15, 2026 | 8.201M |
| September 14, 2026 | 9.283M |
| September 11, 2026 | 9.824M |
| September 10, 2026 | 8.607M |
| September 09, 2026 | 9.013M |
| September 08, 2026 | 9.283M |
| September 04, 2026 | 9.689M |
| September 03, 2026 | 9.418M |
| September 02, 2026 | 10.77M |
| September 01, 2026 | 9.824M |
| August 31, 2026 | 10.64M |
| August 28, 2026 | 10.23M |
| August 27, 2026 | 10.77M |
| August 26, 2026 | 10.91M |
| August 25, 2026 | 10.91M |
| August 24, 2026 | 10.64M |
| August 21, 2026 | 10.50M |
| August 20, 2026 | 9.689M |
| August 19, 2026 | 11.72M |
| August 18, 2026 | 10.37M |
| August 17, 2026 | 10.37M |
| August 14, 2026 | 11.99M |
| Date | Value |
|---|---|
| August 13, 2026 | 14.69M |
| August 12, 2026 | 16.59M |
| August 11, 2026 | 16.86M |
| August 10, 2026 | 13.75M |
| August 07, 2026 | 13.88M |
| August 06, 2026 | 12.39M |
| August 05, 2026 | 13.07M |
| August 04, 2026 | 12.94M |
| August 03, 2026 | 10.23M |
| July 31, 2026 | 9.959M |
| July 30, 2026 | 9.148M |
| July 29, 2026 | 8.607M |
| July 28, 2026 | 9.689M |
| July 27, 2026 | 11.04M |
| July 24, 2026 | 11.04M |
| July 23, 2026 | 11.18M |
| July 22, 2026 | 12.66M |
| July 21, 2026 | 14.15M |
| July 20, 2026 | 12.80M |
| July 17, 2026 | 16.72M |
| July 16, 2026 | 17.53M |
| July 15, 2026 | 16.59M |
| July 14, 2026 | 16.72M |
| July 13, 2026 | 19.83M |
| July 10, 2026 | 23.35M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.815B |
| Alnylam Pharmaceuticals, Inc. | 31.72B |
| Anika Therapeutics, Inc. | 265.34M |
| Savara, Inc. | 960.37M |
| Vericel Corp. | 1.980B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -6.572M |
| Total Expenses (Quarterly) | 6.572M |
| EPS Diluted (Quarterly) | -0.6415 |
| Earnings Yield | -131.6% |
| Normalized Earnings Yield | -131.59 |